AstraZeneca Faces Tough Questions About Its Vaccine After Admitting Mistake


“I just can’t figure out where all of the information is coming from and how it’s being combined,” said Natalie Dean, biostatistician and expert in vaccine study design at the University of Florida. She wrote on Twitter that AstraZeneca and Oxford “get poor marks for transparency and accuracy when it comes to the results of vaccination trials they report”.

As AstraZeneca’s shares fell on Monday, executives at the company held several private conference calls with industry analysts, disclosing details not included in the public notice, including how the Covid-19 cases were broken down into different groups. Such disclosures to analysts are not uncommon in the industry, but often lead to criticism of why the details were not made available to the public.

Bigger problems soon arose.

Mr Pangalos told Reuters Monday that the company did not intend for participants to receive half the dose. British researchers conducting the trial had intended to give volunteers the full dose initially, but one misjudgment meant they were mistakenly given half a dose. Mr. Pangalos described the bug as “coincidental,” which allowed researchers to come across a more promising dosage regimen.

For many outside experts, this undermined the credibility of the results as the tightly calibrated clinical trials were not designed to test how well a starting half-strength dose worked.

The company’s initial announcement made no mention of the random nature of the discovery.

“The reality is that it could be a pretty useful mistake,” Pangalos said in an interview with the New York Times on Wednesday. “It didn’t put anyone in danger. It was a dosing mistake. Everyone was moving very quickly. We corrected the error and continued the study without making changes to the study, and we agreed with the regulatory authority to include these patients in the analysis of the study. “

He added, “What is there to reveal? It doesn’t really matter if it was done on purpose or not. “

In the statement attributed to Oxford, Ms. Meixell, the spokeswoman for AstraZeneca, said the error was due to a problem that has since been resolved in how some of the vaccine doses were made.




We don’t spam! Read our privacy policy for more info.

Leave A Reply

Your email address will not be published.